SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.

Amita Patnaik,Funda Meric-Bernstam,Caio Max Sao Pedro Rocha Lima,Francisco Robert,Afshin Dowlati,Hedy L. Kindler,Diwakar Davar,Steven Francis Powell,Phillip M. Garfin,Ani Sarkis Balmanoukian

Journal of Clinical Oncology（2020）

引用 5|浏览25

暂无评分

摘要

TPS3652Background: SGN-CD228A is an investigational antibody-drug conjugate (ADC) that targets CD228, a cell-surface oncofetal protein with prevalent expression in several types of cancer and limit...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要